FY 2023 results announcement (post announcement page update) - Global

FY 2023 results announcement (post announcement page update)

FY 2023 results announcement

Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

– 26 October 2023 – 1 mins read

26 October 2023 – 1 mins read

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Paris (France), 26 October 2023

A word from David Loew – CEO

Desktop Image

Media Image

FY 2023 results presentation & highlights

Discover the key highlights and results presentation, showcasing Ipsen’s performance and dedication to delivering value to our stakeholders.

FY 2023 results presentation

FY 2023 results highlights

Media Image

Investor and analyst conference call

An investor and analyst conference call, with presentations and an interactive Q&A session, took place after the FY 2023 results announcement.

Investor and analyst call replay

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

IPSEN IN BRIEF

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

If you are experiencing difficulties accessing the investor and analyst call replay, please contact: nicolas.bogler@ipsen.com

FY 2023 results announcement (post announcement page update)

- 13 November 2023 - 0 mins read

FY 2023 results announcement

Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

– 26 October 2023 – 1 mins read

26 October 2023 – 1 mins read

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Paris (France), 26 October 2023

A word from David Loew – CEO

Desktop Image

Media Image

FY 2023 results presentation & highlights

Discover the key highlights and results presentation, showcasing Ipsen’s performance and dedication to delivering value to our stakeholders.

FY 2023 results presentation

FY 2023 results highlights

Media Image

Investor and analyst conference call

An investor and analyst conference call, with presentations and an interactive Q&A session, took place after the FY 2023 results announcement.

Investor and analyst call replay

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

IPSEN IN BRIEF

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

If you are experiencing difficulties accessing the investor and analyst call replay, please contact: nicolas.bogler@ipsen.com

Your dedicated contacts

Craig Marks

Vice President, Investor Relations

Nicolas Bogler

Senior Manager, Investor Relations

Related stories